Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune-based cancer therapy products, announced that preclinical data using the Company’s novel drug product, INT230-6, was selected for presentation at the 2015 American Association for Cancer Research (AACR) Annual Meeting. The conference is being held April 18 to 22, 2015 in the Pennsylvania Convention Center in Philadelphia, PA.

The research will be presented in a poster session and is co-authored by Ian B. Walters, MD, Chief Medical Officer, Lewis H. Bender, President & CEO of Intensity Therapeutics, Jay A. Berzofsky, MD, PhD, Chief of the Vaccine Branch at the National Cancer Institute and Masaki Terabe, PhD, Associate Scientist also at the NCI’s Vaccine Branch. The research will also be published in the 2015 Proceedings of the American Association for Cancer Research.

The poster’s title is: INT230-6, a Novel Intratumoral Anticancer Agent, is able to Eradicate Large, Established Tumors and Stimulate Potent Antitumor Immunity.

Detailed information about viewing the poster presentation:
Session Category: Clinical Research
Session Title: Novel Immunomodulators
Session Date and Time: Tuesday Apr 21, 2015 1:00 PM – 5:00 PM
Location: Poster Section 24
Abstract Number: 4295
Presenters: Ian B. Walters and Lewis H. Bender

About INT230-6

INT230-6 is a novel drug product formulation able to diffuse into cancer cells. Using in vivo preclinical models of severe cancer, INT230-6 treatment results in substantial improvement in survival with large tumors in some animals being completely cleared. Complete responders appear to be protected long term from recurrence of cancer. INT230-6 administration has shown an increased recruitment of immune cells to the tumor.